Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients
ConclusionsIn this study, immune checkpoint inhibitors were effective and tolerable for patients aged ≥75 years. The modified G8 screening tool and performance status were associated with the outcome of older non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Geriatrics | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Study